307 results about "Hyaluronidase" patented technology

The invention relates to polygonum multiflorum exosome-like vesicles and application thereof, the polygonum multiflorum exosome-like vesicles are applied to preparation of antioxidant products, anti-inflammatory products and anti-ultraviolet products, the antioxidant products are products for removing one or more of DPPH free radicals, ABTS free radicals and hydroxyl free radicals, the anti-inflammatory products are products for inhibiting hyaluronidase, and the anti-ultraviolet products are products for removing one or more of DPPH free radicals, ABTS free radicals and hydroxyl free radicals. And the anti-ultraviolet product is a product capable of absorbing UVB. Compared with the prior art, the polygonum multiflorum exosome-like vesicles prepared by the method disclosed by the invention are low in cost and large in treatment capacity, and the obtained polygonum multiflorum exosome-like vesicles have excellent oxidation resistance, inflammation resistance and ultraviolet resistance.

The present invention is related to the field of protein engineering technology which increases the enzymatic activity and thermal stability of human hyaluronidase which is an enzyme that hydrolyzes hyaluronic acid; and more particularly to hyaluronidase PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions in the region corresponding to the alpha-helix region and its linker region in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1 and in which one or more amino acid residues at the N-terminus and / or the C-terminus are selectively cleaved additionally.Specifically, the present invention relates to PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions selected from the group consisting of T341A, T341C, T341G, S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence of SEQ ID NO: 1, and additionally comprise the substitution of amino acids located in the alpha-helix 8 region and / or a linker region between alpha-helix 7 and alpha-helix 8 in the amino acid sequence of wild-type PH20, and in which one or more amino acids located at the N-terminal and C-terminal regions are deleted.

The invention provides a method for preparing ultra-small molecular zinc hyaluronate, and relates to the field of hyaluronate. The method comprises the following steps: carrying out enzymolysis on macromolecular sodium hyaluronate by using leech hyaluronidase to obtain ultra-small molecular sodium hyaluronate; the method comprises the following steps: adsorbing ultra-small molecular sodium hyaluronate by using anion exchange resin, eluting by using a zinc salt solution, and reacting the obtained eluent to obtain ultra-small molecular zinc hyaluronate; the average molecular weight of the ultra-small molecular sodium hyaluronate is 600 Da to 1000 Da. The whole process is simple, the obtained ultra-small molecular zinc hyaluronate is high in zinc content, free of sodium ion residues and high in preparation yield, an organic solvent is not needed in the whole production process, and the method is suitable for industrial production.

The invention relates to the technical field of deep processing of paeonia ostii, in particular to paeonia ostii peptide capable of whitening, moisturizing, tightening and promoting collagen synthesis as well as a preparation method and application of the paeonia ostii peptide. The paeonia ostii flower peptide capable of whitening, moisturizing, tightening and promoting collagen synthesis is prepared through water bath, homogenization, alkali extraction and acid precipitation pretreatment, three times of enzymolysis through compound enzyme of acid protease, cellulase and pectinase and alkaline protease and solid-liquid separation, operation is easy, the requirement for equipment is low, and the paeonia ostii flower peptide is suitable for industrial large-scale production. The prepared paeonia ostii flower peptide has good inhibition capability on tyrosinase, hyaluronidase and elastinase, and also has excellent anti-saccharification and anti-inflammatory effects. Besides, five paeonia ostii active peptide fragments are screened out, are high in activity and non-toxic, can be combined with tyrosinase, hyaluronidase, MMP-1, MMP-3 and COX-2 receptor protein, and have the effects of whitening, moisturizing, tightening and promoting collagen synthesis.

The invention relates to the field of preparation of sodium hyaluronate, in particular to a preparation method of low-molecular-weight sodium hyaluronate. The method specifically comprises the following steps: stirring and dissolving high-molecular-weight sodium hyaluronate powder into water at 45-60 DEG C to obtain a high-molecular-weight sodium hyaluronate solution; cooling to 35-45 DEG C, adding a buffer solution, uniformly mixing, and then adding papain and hyaluronidase in a mass ratio of (2-3): (3-6) to carry out enzymolysis reaction, so as to obtain enzymatic hydrolysate; adding a sodium hydroxide solution into the enzymatic hydrolysate, adjusting the pH value to 7.5-9.0, heating to 80-90 DEG C, treating for 20-40 minutes, and filtering to obtain a low-molecular-weight sodium hyaluronate solution; and performing spray drying. The preparation method is simple in process, mild in condition and free of damage to the product structure, and the prepared low-molecular-weight sodium hyaluronate is high in purity, uniform in molecular weight distribution and good in permeability.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL- 13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL- 13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL- 13). Also described herein are compositions and combinations comprising an antibody or an antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL- 13, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention belongs to the technical field of plant fermentation, and relates to fructus arctii fermentation liquor with soothing and anti-inflammatory effects as well as a preparation method and application of the fructus arctii fermentation liquor. The fructus arctii fermentation liquid is obtained by fermenting fructus arctii through schizosaccharomyces pombe JM2-16, and the fructus arctii fermentation liquid is obtained by fermenting fructus arctii through schizosaccharomyces pombe JM2-16. According to the invention, after the fructus arctii is used as a raw material and is fermented by the schizosaccharomyces pombe, the hyaluronidase inhibition capability, the elastase inhibition capability and the DPPH free radical scavenging capability of the fermentation product can be improved, so that the fermentation product with better soothing, anti-inflammatory and anti-oxidation capabilities is obtained, and the requirements of the market on efficient, natural and safe skin care components are met.

The invention belongs to the technical field of medical biological materials, and particularly relates to a sodium hyaluronate gel regeneration filler for injection and a preparation method and application thereof.The sodium hyaluronate gel serves as a carrier to disperse acellular matrix particles, the sodium hyaluronate gel forms a micron-sized porous structure in the cross-linking process through a microbubbling technology, and the sodium hyaluronate gel is prepared into the sodium hyaluronate gel regeneration filler for injection and the preparation method and application of the sodium hyaluronate gel regeneration filler. A local cross-linked network is strengthened by combining a secondary cross-linking process, high elastic modulus is realized while the content of sodium hyaluronate is reduced, so that the porous structure has excellent instant filling and shaping capability and controllable degradation behavior, the porous structure can promote permeation of hyaluronidase, the degradation period of the hyaluronidase is matched with the tissue regeneration process, and the tissue regeneration effect is improved. And the acellular matrix particles can continuously induce adhesion, migration, proliferation and differentiation of endogenous cells of tissues, synergistically promote in-situ tissue regeneration, effectively reduce repeated injection requirements and reduce long-term complication risks, and have a good application prospect in soft tissue filling and repairing.

The invention provides a prinsepia utilis royle extract as well as a preparation method and application thereof, and the preparation method comprises the following steps: picking prinsepia utilis royle seeds, removing epicarp from the prinsepia utilis royle seeds, dehydrating to obtain dried kernels, preparing prinsepia utilis royle crude oil from the kernels by a subcritical extraction method, refining the crude oil by a deodorization vacuum process to obtain refined non-winterized prinsepia utilis royle oil, and drying the refined non-winterized prinsepia utilis royle oil to obtain the prinsepia utilis royle extract. And performing cold tank winterization treatment on the refined non-winterized prinsepia utilis royle oil to obtain the refined winterized prinsepia utilis royle oil. The prinsepia utilis royle extract obtained by the embodiment of the invention has good effects of resisting oxidation, inhibiting tyrosinase, inhibiting hyaluronidase, inhibiting elastinase, repairing zebra fish and the like.

The invention relates to an enzyme response antibacterial carbon dot and a preparation method and application thereof.The carbon dot takes a copper-doped carbon dot as a core and is covalently grafted with a hyaluronic acid shell layer through amidation reaction to form a composite nano material Cu-CDs (at) HA, specifically, soluble copper salt and folic acid are subjected to a hydrothermal reaction to obtain the copper-doped carbon dot, carboxyl is activated through EDC / NHS in a buffer system, and the carbon dot is prepared. And performing grafting reaction with hyaluronic acid to obtain a target product. The hyaluronidase-containing antibacterial composition can be specifically degraded and release antibacterial components under the action of hyaluronidase, shows good bacterial responsive bactericidal performance, has the minimum inhibitory concentrations of 8 g / mL and 16 g / mL for staphylococcus aureus and escherichia coli respectively, and has peroxidase-like activity and free radical scavenging capacity. The antibacterial carbon dots can be used for preparing intelligent wound dressings, antibacterial coatings and other biomedical materials, and have the advantages of responsive drug release, efficient antibacterial property and promotion of wound repair.

The invention relates to the technical field of polypeptide detection, and particularly discloses a method for determining the content of human epidermal growth factors in sodium hyaluronate composite gel. The method comprises the following steps: S1, carrying out enzymolysis on sodium hyaluronate in the sodium hyaluronate composite gel by using an enzyme to obtain a test solution; s2, measuring a blank matrix solution containing no human epidermal growth factors, and adding enzyme for enzymolysis to obtain a blank matrix solution; s3, measuring the human epidermal growth factor, and diluting the human epidermal growth factor with the blank matrix solution to obtain a reference substance solution; and S4, detecting the test solution and the reference solution by using a high performance liquid chromatography and an ultraviolet detector, and determining the content of the human epidermal growth factor by using an external standard method. According to the method, hyaluronidase is used for pre-treating the test sample, macromolecular and high-viscosity sodium hyaluronate is subjected to enzymolysis to form micromolecular sugar, the method is compatible with the same liquid chromatography separation system, the content of the human epidermal growth factors in the test sample is measured by adopting an HPLC (High Performance Liquid Chromatography) combined ultraviolet detector, and the method is high in specificity, high in accuracy, low in detection limit and good in repeatability.

The present invention relates to a cartilage tissue single cell extraction kit and an extraction method thereof, the kit comprises: (1) a first enzyme for enzymatic hydrolysis, the first enzyme for enzymatic hydrolysis comprising one or more of trypsin, chondroitinase ABC and fucosidase; (2) a second enzyme for enzymolysis, wherein the second enzyme for enzymolysis comprises collagenase II, neutral protease II, hyaluronidase and Dnase I; and (3) a basic solution, wherein the basic solution comprises a basic culture medium and / or a buffer solution. The invention also provides a method for extracting single cells from cartilage tissues by using the kit. The cartilage tissue single-cell suspension prepared by the method has the advantages of high cell yield, high activity and the like, and has a wide application prospect.

The invention discloses a novel colorectal cancer organoid culture method, which obviously improves the activity of primary cells (more than or equal to 90%) and the forming efficiency of the organoid (the success rate is more than 95%) through alcohol gradient cleaning, collagenase-hyaluronidase combined digestion and stent-free culture technologies. The improved culture medium takes R-Spondin1 as a core, nicotinamide and a small-molecule inhibitor are combined, and long-term amplification of organoids (passage is more than or equal to 10 times) is supported. The method is suitable for individualized drug screening, tumor microenvironment simulation and drug resistance mechanism research, has the advantages of high efficiency, stability and low cost, and provides a reliable model for precise medical treatment of colorectal cancer.

The invention provides a method for screening a hyaluronidase (HAase) inhibitor, and belongs to the technical field of medicines. The method comprises the following steps: firstly, rapidly identifying a natural product with HAase inhibition activity by adopting a fluorescence sensing technology according to the principle that carbon quantum dots (CDs) are used as a fluorescence probe, hyaluronic acid (HA) modified gold nanoparticles are used as a quencher, and the fluorescence of the CDs can be quenched by the quencher; when HAase exists, HA can be enzymatically decomposed to release CDs, and fluorescence recovery is caused; when a screened sample has HAase inhibition activity, CDs fluorescence recovery can be prevented. And 2, capturing components in a sample capable of inhibiting HAase activity by virtue of an affinity chromatography technology, immobilizing HAase on a carrier material by virtue of a method, eluting by virtue of a solvent to obtain components capable of being combined with HAase, and identifying the components by virtue of a liquid chromatography-mass spectrometry technology. According to the method, the HAase inhibitor can be rapidly and accurately screened from natural products.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL-4Rα in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL-4Rα biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-4Rα antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL-4). Also described herein are compositions and combinations comprising an antibody or antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL-4Rα, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention is related to the field of protein engineering technology which increases the enzymatic activity and thermal stability of human hyaluronidase which is an enzyme that hydrolyzes hyaluronic acid; and more particularly to hyaluronidase PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions in the region corresponding to the alpha-helix region and / or its linker region in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1 and in which one or more amino acid residues at the N-terminus and / or the C-terminus are selectively truncated additionally.Specifically, the present invention relates to PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions selected from the group consisting of T341A, T341C, T341G, S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence of SEQ ID NO: 1, and additionally comprise the substitution of amino acids located in the alpha-helix 8 region and / or a linker region between alpha-helix 7 and alpha-helix 8 in the amino acid sequence of wild-type PH20, and in which portion(s) of amino acids located at the N-terminal and C-terminal regions are deleted.

The invention discloses a composition with relieving and itching relieving effects as well as a preparation method and application thereof, and particularly belongs to the field of cosmetics. The composition comprises the following components: a composite plant extract, polyol and water, the composite plant extract is prepared by compounding a rhizoma polygonati fermentation liquid, a Chinese herbaceous peony extract and a caulerpa lentillifera extract; the rhizoma polygonati fermentation liquor is obtained by carrying out compound fermentation on lactobacillus pentosus and bacillus subtilis. The soothing and itching relieving composition provided by the invention has an excellent soothing effect, the soothing and itching relieving composition provided by the invention has an excellent in-vitro hyaluronidase inhibition effect, and the in-vitro hyaluronidase inhibition rate reaches 60% or above.

The invention discloses a tissue dissociation liquid, a tissue dissociation method and application thereof, and relates to the technical field of cell biology. In a DMEM / F12 culture medium, the tissue dissociation liquid only contains the following raw materials in concentration: 0.5 to 3 mg / mL of type II collagenase, 0.5 to 2 mg / mL of type IV collagenase, 0.5 to 2 mg / mL of hyaluronidase, 10 to 18 [mu] M of Y27632 and 80 to 150 [mu] g / mL of primocin. The tissue dissociation liquid provided by the invention can dissociate normal tissues or tumor tissues into single cells or cell clusters, the single cells obtained by the digestion method are high in proliferation rate and easy to successfully culture, and the tissue dissociation liquid has the technical advantages that the cell yield and survival rate are maintained at a relatively high level. Therefore, the tissue dissociation liquid provided by the invention has good application prospects in tumor tissue dissociation, cell line construction and organoid model construction.

Described herein are hyaluronidase particles, compositions comprising the same, and methods of making and using the same. The compositions of the invention may comprise hyaluronidase particles and may be a suspension. Granules comprising hyaluronidase may have a moisture content of less than about 15% by weight of the particle and / or a water activity of less than about 0.9. In some embodiments, the methods of the invention may comprise administering to a subject a particle comprising hyaluronidase subcutaneously, intramuscularly, and / or intradermally, where the particle has a moisture content of less than about 15% by weight of the particle and / or a water activity of less than about 0.9.

The invention discloses a Chinese forest frog peptide or a salt thereof. The Chinese forest frog peptide comprises an amino acid sequence Asn-Pro-Asp-Tyr-Arg as shown in SEQ ID NO: 1. Moisturizing and relieving mechanisms of the peptide are explored through molecular docking, and we find that the Chinese forest frog peptide as shown in SEQ ID NO: 1 can be effectively docked with hyaluronidase and TLR4-MD2. According to the present invention, chemical synthesis and activity evaluation are performed on the Chinese forest frog peptide Asn-Pro-Asp-Tyr-Arg (NPDYR) represented by SEQ ID NO: 1, and the Chinese forest frog peptide shows certain repairing, moisturizing and soothing activities, can be used as a functional component in cosmetics, and has good application prospects.

The present invention provides a composition for reducing or eliminating vascular occlusion caused by hyaluronic acid soft tissue dermal fillers. [Solution] This disclosure provides for compositions comprising hyaluronidase, apparatus for housing such compositions, and methods and uses of such compositions and apparatus for reducing or eliminating hyaluronic acid-induced blockages in one or more blood vessels supplying an individual's eye; methods and uses of such compositions and apparatus for reducing or inhibiting vascular occlusion of an individual's eye; and methods and uses of such compositions and apparatus for reducing or inhibiting hyaluronic acid-induced vision loss in an individual.

Provided herein is a hypervesiculating Escherichia coli Nissle (ΔECHy) bacterium engineered to produce outer membrane vesicles (OMVs), said OMVs packaging a fusion peptide including cytolysin A (ClyA) and hyaluronidase (Hy). Also provided are methods of remodeling a tumor, methods of treating cancer, and pharmaceutical compositions including the engineered ΔECHy bacterium.

This invention relates to the field of microbial technology, specifically to a *Lactobacillus plantarum* YYS-B1 strain with hyaluronidase inhibitory activity and its applications. *Lactobacillus plantarum* (… Lactiplantibacillus plants YYS-B1 was deposited at the China General Microbiological Culture Collection Center (CGMCC) on June 12, 2023, with accession number CGMCC No. 27599. This *Lactobacillus plantarum* YYS-B1 exhibits excellent acid and bile salt resistance, enabling it to successfully reach the intestines and exert its probiotic effects. It also demonstrates outstanding anti-allergic, anti-inflammatory, and antioxidant capabilities, specifically exhibiting high hyaluronidase inhibition, strong free radical scavenging ability, and a good inhibitory effect on inflammatory responses caused by allergies. Therefore, it has significant application value and can be used in the development of functional products.

The present invention provides: a Hyal1 variant in which, in wild-type human hyaluronidase Hyal1 comprising glutamic acid 131 as a catalytic amino acid, at least one amino acid among amino acids adjacent to the catalytic amino acid, i.e., glutamic acid 131 in primary and tertiary structures is substituted with an acidic, polar or basic amino acid; a method for producing the Hyal1 variant; a nucleic acid applicable to the production of the Hyal1 variant; an expression vector; a host cell; and a Hyal1 variant preparation or use thereof. The hyaluronidase Hyal1 variant of the present invention can effectively degrade hyaluronic acid not only at acidic pH but also at neutral pH, and thus is highly applicable.

The invention discloses a whitening, anti-wrinkle, firming and soothing multi-effect composition, which is prepared from the following raw material components: nicotinamide, hydroxypropyl tetrahydropyrantriol, p-hydroxyacetophenone, glycerol, 1, 2-pentanediol, 1, 2-hexanediol, a barley extract composition, panthenol, a radix gentianae extract composition, an oat kernel extract composition and the balance of water. The barley extract, the radix gentianae extract and the oat kernel extract are added into the whitening, anti-wrinkle, firming and soothing multi-effect composition, so that melanosome can be inhibited from being transferred to the skin surface, DNA damage caused by UV is repaired, photoimmunosuppression is intervened, elastase and hyaluronidase are inhibited, and the whitening, anti-wrinkle, firming and soothing multi-effect composition has the advantages that the whitening, anti-wrinkle, firming and soothing functions are realized; the face cream prepared from the multi-effect composition for whitening, resisting wrinkles, tightening and relieving has the effects of whitening, resisting wrinkles, tightening and relieving.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and / or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

The present invention relates to compositions and methods for treating cancer in a patient comprising administering to the patient subcutaneously every six weeks a specific amount of a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g., pemmumab) or an antigen-binding fragment thereof, with or without a hyaluronidase. In particular embodiments, the amount of the anti-PD-1 antibody or antigen-binding fragment thereof is from about 600 mg to about 1000 mg. In particular embodiments, the administration is performed once every about three weeks, and the amount of the anti-PD-1 antibody or antigen-binding fragment thereof is from about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembromab or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising specific doses of an anti-PD-1 antibody or antigen-binding fragment thereof, and uses thereof for the treatment of cancer.